Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis links with Infinity

March 13, 2006 | A version of this story appeared in Volume 84, Issue 11

Novartis and Infinity Pharmaceuticals have joined forces to develop cancer drugs that target members of the Bcl-2 protein family. Protein-protein interactions among the Bcl-2 family are critical to cancer cell survival, but small molecules have traditionally proven unsuccessful in modulating those interactions. Infinity says its Diversity Oriented Synthesis can tackle the problem by generating a library of natural-product-like compounds that can be leveraged by Novartis' drug discovery and development team. Infinity will receive a $30 million up-front licensing fee, research funding during the first two years of the pact, and milestone payments. Infinity says total payments could exceed $400 million. Novartis will also make an equity investment in Infinity, and has agreed to invest in Infinity's initial public offering, should it take place within the next two years.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.